Research Topics
Genomes and GenesSpecies | A TefferiSummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
Is bone marrow biopsy essential for the diagnosis of essential thrombocythemia?Ayalew Tefferi
Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Lymphoma 47:1724-5. 2006
Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lectureAyalew Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leuk Res 36:1481-9. 2012....
JAK inhibitors for myeloproliferative neoplasms: clarifying facts from mythsAyalew Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 119:2721-30. 2012....
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617FA Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 26:475-80. 2012..Our observations suggest that IDH mutations in PMF are independent predictors of leukemic transformation and raise the possibility of leukemogenic collaboration with JAK2V617F...
Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasmsAnimesh Pardanani
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 30:1087-94. 2012..Because of immediate practical applicability, we chose plasma immunoglobulin free light chain (FLC) concentration as the biomarker of interest...
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and managementAyalew Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Hematol 87:285-93. 2012..Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures. Screening for clinically significant AvWS is recommended before administrating aspirin in the presence of extreme thrombocytosis...
If you feed them, they will come: a prospective study of the effects of complimentary food on attendance and physician attitudes at medical grand rounds at an academic medical centerColin M Segovis
Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
BMC Med Educ 7:22. 2007..The present study examined whether attendance at medical grand rounds increased after providing complimentary food to attendees and also assessed attendee attitudes about complimentary food...
Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasiaAyalew Tefferi
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 104:1656-60. 2005..The current prospective study addresses this issue in the context of currently accepted independent prognostic variables...
Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatmentAyalew Tefferi
Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 80:75-83. 2005....
Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithmsA Tefferi
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 22:14-22. 2008..The current review highlights these changes and also provides diagnostic algorithms that are tailored to routine clinical practice...
JAK2 in myeloproliferative disorders is not just another kinaseAyalew Tefferi
Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cell Cycle 4:1053-6. 2005..Taken together, these observations suggest that JAK2(V617F) is an acquired myeloid lineage-specific mutation that engenders a pathogenetic relevance for the PV phenotype in MPD...
Modern diagnosis and treatment of primary eosinophiliaA Tefferi
Divisions of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Acta Haematol 114:52-60. 2005..Allogeneic transplantation offers a viable treatment option for drug-refractory cases...
bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatmentAyalew Tefferi
Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 80:1220-32. 2005..In this article, we outline contemporary diagnostic algorithms for each of these disorders and provide an evidence-based approach to management...
Introduction to a cancer symposium for the practitionerAyalew Tefferi
Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 80:1085-6. 2005
JAK2 mutations and clinical practice in myeloproliferative neoplasmsAyalew Tefferi
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Cancer J 13:366-71. 2007....
Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia veraMichelle A Elliott
Mayo Clinic, 200 First Street SW, West 10 A, Division of Hematology, Rochester, MN 55905, USA E mail
Curr Hematol Rep 3:344-51. 2004..Additional patient management issues are raised during systemic anticoagulation and surgery. This review summarizes putative pathogenetic mechanisms of bleeding and their management in ET and PV...
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survivalA Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
Leukemia 22:756-61. 2008..We conclude that low V617F allele burden in PMF might indicate the presence of an overriding V617F-negative clone that confers a more aggressive disease phenotype...
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosisA Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 23:905-11. 2009..05). We conclude that TET2 mutations occur in both JAK2V617F-positive and -negative MPN, are more prevalent in older patients, display similar frequencies across MPN subcategories and disease stages, and hold limited prognostic relevance...
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlatesA Tefferi
Divisions of Hematology and Hematopathology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 23:900-4. 2009..98). We conclude that TET2 mutations are frequent in SM, segregate with KITD816V and influence phenotype without necessarily altering prognosis...
Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysisAyalew Tefferi
Mayo Clinic, Rochester, MN, USA
Leuk Res 33:662-4. 2009..This preliminary report suggests a potential value for array CGH in terms of both clinical diagnostics and genomic research in MPNs...
Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?Ayalew Tefferi
Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Leuk Lymphoma 49:1225-7. 2008
Systemic mastocytosis: current concepts and treatment advancesAyalew Tefferi
Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
Curr Hematol Rep 3:197-202. 2004..Cladribine has been shown to be effective in patients who develop resistance to interferon treatment...
20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosisAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Eur J Haematol 80:386-90. 2008....
The indolent natural history of essential thrombocythemia: a challenge to new drug developmentAyalew Tefferi
Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 80:97-8. 2005
Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosisAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Int J Hematol 79:441-7. 2004..The bone marrow histologic phenotype of these imatinib-sensitive eosinophilic disorders includes systemic mastocytosis, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, and atypical chronic myeloproliferative disorder...
Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemiaAyalew Tefferi
Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Br J Haematol 131:166-71. 2005..However, compared with the PRV-1 assay, mutation screening for JAK2(V617F) displayed greater accuracy in distinguishing PV from SP...
Polycythemia vera: scientific advances and current practiceAyalew Tefferi
Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Semin Hematol 42:206-20. 2005..Despite recent progress in the field, several important issues remain controversial. In this review, we will present the areas of agreement, but also point out where the authors' personal viewpoints differ...
Eosinophilia: secondary, clonal and idiopathicAyalew Tefferi
Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Br J Haematol 133:468-92. 2006..The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment...
Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617FAyalew Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Semin Thromb Hemost 33:313-20. 2007..Whether the presence of this specific mutation or its allele burden modifies the risk of thrombosis in patients with MPDs currently is under investigation...
Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular systemAyalew Tefferi
Division of Hematology, Mayo Clinic College of Medicine, Rochester 55905, USA
Best Pract Res Clin Haematol 19:365-85. 2006..Such progress is paving the way for a transition from a histologic to a semi-molecular classification system that preserves conventional terminology, while incorporating new information on molecular pathogenesis...
The diagnosis of polycythemia vera: new tests and old dictumsAyalew Tefferi
Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Best Pract Res Clin Haematol 19:455-69. 2006..Recent discoveries of myeloproliferative-disease-specific molecular markers, including the JAK2 V617F tyrosine kinase mutation that is found in the majority of patients with PV, provide further support for such a measure...
Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic testsAyalew Tefferi
Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Mayo Clin Proc 82:599-604. 2007....
Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institutionAyalew Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 109:2083-8. 2007..Two other PSSs, Cervantes and Mayo, were recently reported as being more useful in younger patients. The current study compares these 3 PSSs among all age groups...
Suppressors of cytokine signaling and regulation of clonal erythropoiesisAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Leuk Lymphoma 48:7-8. 2007
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)Ayalew Tefferi
Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
Blood 108:1497-503. 2006..Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly...
Atypical myeloproliferative disorders: diagnosis and managementAyalew Tefferi
Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Mayo Clin Proc 81:553-63. 2006....
Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlatesAyalew Tefferi
Division of Hematology, 200 First Street SW, Mayo Clinic, Rochester, MN 55905, USA
Leuk Res 30:677-80. 2006..In the current study, we show that microcytosis is a frequent laboratory feature in agnogenic myeloid metaplasia and investigate its clinical relevance in the particular setting...
Pathogenesis of myelofibrosis with myeloid metaplasiaAyalew Tefferi
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Clin Oncol 23:8520-30. 2005..This latter phenomenon, through neutrophil-derived elastase, could also underlie the abnormal peripheral-blood egress of myeloid progenitors in MMM...
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia veraAyalew Tefferi
Division of Hematology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, and Department of Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Cancer 106:631-5. 2006..Several studies have recently reported on the occurrence of a JAK2(V617F) mutation in myeloid cells from the majority of patients with polycythemia vera (PV). The clinical relevance of this novel observation currently is under study...
New insights into the pathogenesis and drug treatment of myelofibrosisAyalew Tefferi
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Curr Opin Hematol 13:87-92. 2006..Advances have also been meager in terms of treatment for disease complications, including anemia, splenomegaly, and leukemic transformation...
Essential thrombocythemia: scientific advances and current practiceAyalew Tefferi
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Curr Opin Hematol 13:93-8. 2006....
Mutation screening for JAK2V617F: when to order the test and how to interpret the resultsAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 30:739-44. 2006..Therefore, mutation screening for JAK2V617F can be considered as a myeloid-specific clonality assay and it is diagnostically most useful in the evaluation of "polycythemia"...
Iron chelation therapy for myelodysplastic syndrome: if and whenAyalew Tefferi
Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 81:197-8. 2006
Lenalidomide therapy in myelofibrosis with myeloid metaplasiaAyalew Tefferi
Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Blood 108:1158-64. 2006..We conclude that lenalidomide engenders an intriguing treatment activity in a subset of patients with MMM that includes an unprecedented effect on peripheral blood and bone marrow abnormalities...
The diagnostic interface between histology and molecular tests in myeloproliferative disordersAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
Curr Opin Hematol 14:115-22. 2007..This review discusses how this process is unfolding in myeloproliferative disorders...
A contemporary approach to the diagnosis and management of polycythemia veraAyalew Tefferi
Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Curr Hematol Rep 2:237-41. 2003..This review outlines a practical approach to diagnosis, in addition to treatment of life-threatening and non-life-threatening complications of PV...
The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaosAyalew Tefferi
Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Cancer 115:3842-7. 2009..The revised WHO document continues to promote the recognition of histologic categories as a necessary first step toward the genetic characterization of myeloid malignancies...
Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and managementAyalew Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Am J Hematol 86:292-301. 2011..Treatment with busulfan or interferon-a is usually effective in hydroxyurea failures...
Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling studyAyalew Tefferi
Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 29:1356-63. 2011..This study describes the spectrum of plasma cytokine abnormalities in primary myelofibrosis (PMF) and examines their phenotypic correlates and prognostic significance...
Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategiesAyalew Tefferi
Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 29:573-82. 2011..The unmet need for treatment in PMF dictates a different approach for assessing the therapeutic value of new drugs (eg, JAK inhibitors, pomalidomide) or allogeneic stem-cell transplantation...
Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literatureS Kumar
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Ann Hematol 80:430-5. 2001..Here we describe a patient who developed pneumomediastinum, pneumopericardium, subcutaneous emphysema and pneumothorax secondary to severe bronchiolitis obliterans complicating the post bone marrow transplantation course...
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosisA Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 24:1302-9. 2010..The current study clarifies disease- and stage-specific IDH mutation incidence and prognostic relevance in MPN and provides additional evidence for the biological effect of distinct JAK2 haplotypes...
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1A Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 24:1128-38. 2010..However, it is not clear as to whether and how these abnormalities contribute to disease initiation, clonal evolution or blastic transformation...
Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and managementA Tefferi
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood Rev 15:121-31. 2001..Clinicopathologic correlates to these biologic parameters are currently being defined...
Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choicesAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 51:576-82. 2010..Current information on mutational status and response to JAK2 inhibitor drug therapy is too preliminary to draw any conclusions...
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotypeAyalew Tefferi
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 85:14-7. 2010..We conclude that transfusion status in PMF downgrades or upgrades prognosis within specific IPSS categories; transfusion need is a marker of aggressive disease biology in PMF, as it is in myelodysplastic syndromes...
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survivalA Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leukemia 24:105-9. 2010..Allelic distortion from acquired uniparental disomy contributes to the appearance of a more pronounced effect on disease susceptibility in VF-positive patients, when studying clonally affected tissue...
Pomalidomide is active in the treatment of anemia associated with myelofibrosisAyalew Tefferi
Mayo Clinic, 200 First St SW, Rochester MN 55905, USA
J Clin Oncol 27:4563-9. 2009..However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the safety and therapeutic activity of another immunomodulatory drug, pomalidomide...
Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathologyAyalew Tefferi
Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Mol Diagn 13:461-6. 2011..The practice of en bloc screening for JAK2V617F, JAK2 exon 12, and MPL mutations is scientifically irrational and economically irresponsible...
The pathogenesis of chronic myeloproliferative diseasesA Tefferi
Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Int J Hematol 73:170-6. 2001..This review discusses some of the current and past observations regarding the pathogenesis of chronic myeloproliferative disorders...
Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasiaAyalew Tefferi
Mayo Clinic, Rochester, MN 55905, USA
Blood 99:3854-6. 2002..In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit...
Long-term outcome of treatment with ruxolitinib in myelofibrosisAyalew Tefferi
Mayo Clinic, Rochester, MN
N Engl J Med 365:1455-7. 2011..The control of splenomegaly may not be durable, and the likelihood of leukemic progression or death is not dramatically lowered...
A long-term retrospective study of young women with essential thrombocythemiaA Tefferi
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 76:22-8. 2001..To describe presenting clinical manifestations, long-term disease complications, prognostic indicators, and outcome of pregnancy for women younger than 50 years with essential thrombocythemia...
The forgotten myeloproliferative disorder: myeloid metaplasiaAyalew Tefferi
Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
Oncologist 8:225-31. 2003..New treatment approaches include the use of thalidomide alone or in combination with prednisone and hematopoietic stem cell transplantation...
Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosisAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Mayo Clin Proc 86:1188-91. 2011....
Recent progress in the pathogenesis and management of essential thrombocythemiaA Tefferi
Mayo Clinic, Division of Hematology and Internal Medicine, 200 First Street SW, Rochester, MN 55095, USA
Leuk Res 25:369-77. 2001..Furthermore, randomized, prospective, and controlled retrospective data have provided additional clinical information that has resulted in the development of risk categories and risk-adjusted treatment recommendations...
JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspectiveA Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
Blood Rev 25:229-37. 2011..It is our impression that many more JAK inhibitors need to be evaluated in order to identify the best-in-class in terms of efficacy, toxicity and suitability for future combination treatment programs...
Polycythemia vera: a comprehensive review and clinical recommendationsAyalew Tefferi
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 78:174-94. 2003....
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosineKen H Lim
Divisions of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 84:790-4. 2009....
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophiliaAnimesh Pardanani
Division of Hematology and Internal Medicine, Laboratory Geentics and Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Blood 104:3038-45. 2004..In contrast, only 40% partial response rate was seen in 10 HES cases. FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis...
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapyAnimesh Pardanani
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Blood 102:3093-6. 2003..Screening for the FIP1L1-PDGFRA rearrangement and Asp816Val mutation will advance rational therapy decisions in SMCD...
Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasiaBrijesh Arora
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Haematologica 89:1454-8. 2004..The study also suggests either a megakaryocyte origin or a megakaryocyte effect for the putative angiogenic cytokine...
JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevanceAlexandra P Wolanskyj
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 131:208-13. 2005..Therefore, although the presence of JAK2(V617F) in ET appears to promote a PV phenotype, it might not carry treatment-relevant information...
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasiaRuben A Mesa
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 101:2534-41. 2003..Clinical responses did not correlate with improvements in either intramedullary fibrosis or angiogenesis. THAL-PRED is well tolerated and preliminarily appears to be a promising drug regimen for treating cytopenias in patients with MMM...
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasmsA Pardanani
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 24:1146-51. 2010..This study shows a relatively high incidence of IDH mutations in blast-phase MPN, regardless of JAK2 mutational status, and the occurrence of similar mutations in chronic-phase PMF...
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisRoss L Levine
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Cell 7:387-97. 2005..In vitro analysis demonstrated that JAK2V617F is a constitutively active tyrosine kinase...
In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasiaR A Mesa
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 17:849-55. 2003....
Clinical correlates of JAK2V617F allele burden in essential thrombocythemiaJaya Kittur
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 109:2279-84. 2007..A possible association with thrombotic complication has also been considered...
Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlatesMrinal M Patnaik
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Eur J Haematol 84:518-24. 2010..The current study was designed to provide additional data in this regard...
Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatmentDavid Dingli
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Intern Med 43:540-7. 2004..Among the novel agents tested, thalidomide seems the most promising although newer agents are on the horizon...
Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasiaMichelle A Elliot
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Eur J Haematol 68:175-9. 2002..Consistent with previous observations in animal models, our observations suggest the possibility that altered TPO regulation resulting in sustained ligand excess may have pathogenetic relevance in MMM...
Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide eraShernan G Holtan
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Hematol 83:708-13. 2008..Additional important prognostic factors not taken into account by the IPSS include the baseline erythrocyte indices, lymphocyte count, and clonal burden...
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyureaShireen Sirhan
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Hematol 83:363-5. 2008..02). The current study suggests that JAK2V617F presence identifies PMF patients who are likely to respond to HU therapy, and information on its allele burden helps in assigning the optimal starting dose in individual patients with PV...
Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemiaYinlee Yoong
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Eur J Haematol 74:124-7. 2005..These results are contrary to previous reports that suggested inferior survival as well as poor response to alpha interferon therapy in CML patients carrying der(9) deletions...
Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assayCody A Koch
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 127:34-9. 2004..86% test accuracy). The current study suggests that PRP serotonin concentration might be considered as one of the several biological markers that complement each other for the diagnosis of PV...
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformationNaseema Gangat
Division of Hematology, Department of Medicine, Laboratory Medicine, and Health Sciences Research, Mayo Clinic, Rochester, MN, USA
Br J Haematol 138:354-8. 2007..The current study highlighted the prognostic relevance of leucocytosis on various aspects of the disease in PV...
Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring systemDavid Dingli
Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer 106:623-30. 2006..The new system displayed a stronger discriminative value, between risk categories, compared with currently existing prognostic models...
Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institutionMrinal M Patnaik
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Am J Hematol 85:238-42. 2010..We conclude that neither the SCLL phenotype nor blood eosinophilia is a consistent feature of FGFR1-associated 8p11.2 translocations; conversely, FISH might not always reveal FGFR1 involvement in typical SCLL...
Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytesAnimesh Pardanani
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
Stem Cells 25:2358-62. 2007..These observations suggest that clonal myelopoiesis antedates acquisition of JAK2V617F or MPLW515L/K mutations and that the latter is acquired in a lympho-myeloid progenitor cell...
Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasiaTerra L Reeder
Mayo Clinic, Rochester, MN 55905, USA
Blood 101:1981-3. 2003..The current study provides direct evidence for the clonal involvement of both B and T lymphocytes in MMM. A larger study is needed to clarify the relevance of the observed interpatient heterogeneity in clonal constitution...
Molecular diagnosis of myeloproliferative neoplasmsMrinal M Patnaik
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Expert Rev Mol Diagn 9:481-92. 2009..In patients with clonal eosinophilic disorders and mast cell disease, the use of molecular diagnostics to identify novel mutations and gene rearrangements, has resulted in superior diagnostic and therapeutic strategies...
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over timeTerra L Lasho
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 135:683-7. 2006..We conclude that MPLW515L/K and JAK2V617F are both early events in MMM and allele burden, rather than the mere presence of these mutations, might be relevant to phenotypic variation in myeloproliferative disorders...
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutationsA Pardanani
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 21:1658-68. 2007..Therapeutic efficacy of TG101209 was demonstrated in a nude mouse model. Furthermore, TG101209 suppressed growth of hematopoietic colonies from primary progenitor cells harboring JAK2V617F or MPL515 mutations...
Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host diseaseS Kumar
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Bone Marrow Transplant 30:161-5. 2002..03). Relapse-free survival was similar for the two groups. We conclude that omitting day +11 MTX appears to increase the risk of severe acute GVHD...
WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutationsM M Patnaik
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 24:1283-9. 2010....
Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patientsBrijesh Arora
Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA
Br J Haematol 128:42-8. 2005..The current prospective study does not support an independent prognostic value for PB CD34 count in MMM...
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromesDavid P Steensma
Mayo Clinic and Mayo Clinic College of Medicine, Rochester MN 55905, USA
Blood 106:1207-9. 2005..The current observation strengthens the specific association between JAK2 V617F and classic MPD, but also suggests an infrequent occurrence in other myeloid disorders...
Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell diseaseAnimesh Pardanani
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 27:739-42. 2003..In SMCD, the presence of D816V mutation was significantly associated with advanced age, an aggressive clinical course, increased bone marrow mast cell content, and chronic myelomonocytic leukemia...
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatmentAyalew Tefferi
Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 80:390-402. 2005..These issues are discussed within the context of clinical practice...
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disordersAnimesh Pardanani
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 101:3391-7. 2003..Myocardial biopsy revealed eosinophilic infiltration and degranulation, and the cardiogenic shock was reversed with the prompt institution of corticosteroid therapy...
Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective studyAnimesh Pardanani
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 77:1169-75. 2002..In contrast, BM angiogenesis, reticulin fibrosis, and levels of MC mediators showed no prognostic relevance...
